http://www.zibb.com/all/theme/cq/Celgene+Corporation Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Wed, 18 Nov 2009 09:31:00 GMTWed, 18 Nov 2009 09:31:00 GMT608831http://www.zibb.com/all/theme/cq/Celgene+Corporation http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5678206/Critical+Alerts+For+Visa+Schlumberger+Celgene+Illumina+and+American+Water+Works+Released+By+Seven+Summits+ResearchSeven Summits Research issues PriceWatch Alerts for V, SLB, CELG, ILMN, and AWK. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/111809B (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alertshttp://www.zibb.com/article/5678206/Critical+Alerts+For+Visa+Schlumberger+Celgene+Illumina+and+American+Water+Works+Released+By+Seven+Summits+ResearchCelgene CorporationWed, 18 Nov 2009 09:31:00 GMThttp://www.genengnews.com/news/bnitem.aspx?name=68851356Celgene and Innate Pharma agreed to work together to carry out a Phase II trial evaluating a combination of their treatments for multiple myeloma. Celgene’s Revlimid® andhttp://www.genengnews.com/news/bnitem.aspx?name=68851356Celgene CorporationWed, 18 Nov 2009 00:00:00 GMThttp://www.fool.com/investing/small-cap/2009/11/11/these-are-the-markets-10-best-stocks.aspxYes, it is. You learn pretty rapidly in this business that the best way to make money in the market is to invest for the long term, and you recognize that volatility is part of the ride.http://www.fool.com/investing/small-cap/2009/11/11/these-are-the-markets-10-best-stocks.aspxCelgene CorporationWed, 11 Nov 2009 20:51:28 GMThttp://seekingalpha.com/article/171182-celgene-buy-on-a-pullback?source=feedOckham Research submits: So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008.http://seekingalpha.com/article/171182-celgene-buy-on-a-pullback?source=feedCelgene CorporationWed, 04 Nov 2009 17:09:36 GMThttp://www.cnbc.com/id/33603726/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahoo], namely its profitable treatment franchises and full pipeline. But “there’s nothing so compelling at this moment that makes me want to jump in,” he said of the stock.http://www.cnbc.com/id/33603726/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahooCelgene CorporationWed, 04 Nov 2009 00:11:52 GMThttp://www.bloggingstocks.com/2009/10/27/celgene-celg-bet-on-biotech-for-offense-and-defense/Filed under: Newsletters, Stocks to Buy"I am recommending <ahttp://www.bloggingstocks.com/2009/10/27/celgene-celg-bet-on-biotech-for-offense-and-defense/Celgene CorporationTue, 27 Oct 2009 16:20:00 GMThttp://www.marketwatch.com/story/celgene-earnings-rise-in-quarter-2009-10-22?siteid=rssNEW YORK (MarketWatch) -- Celgene Corp. said Thursday that third-quarter earnings were $217 million, or 46 cents a share, compared to $137 million, or 29 cents a share, in the year-ago period. Celgene's adjusted earnings were 56 cents a share. Revenue was $695 million compared to $592 million.http://www.marketwatch.com/story/celgene-earnings-rise-in-quarter-2009-10-22?siteid=rssCelgene CorporationThu, 22 Oct 2009 11:49:32 GMThttp://finance.yahoo.com/news/Ahead-of-the-Bell-Celgene-apf-2453338469.html?x=0&.v=1NEW YORK (AP) -- Celgene Corp. shares could stage a recovery by the end of this year due to increased use of the cancer drug Revlimid,http://finance.yahoo.com/news/Ahead-of-the-Bell-Celgene-apf-2453338469.html?x=0&.v=1Celgene CorporationMon, 21 Sep 2009 11:56:38 GMThttp://www.biospace.com/news_story.aspx?StoryID=156323&full=1SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced its presentation at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 1:30 p.m.http://www.biospace.com/news_story.aspx?StoryID=156323&full=1Celgene CorporationThu, 17 Sep 2009 00:00:00 GMThttp://www.forbes.com/2009/09/16/celgene-biotechnology-thalomid-personal-finance-investing-ideas-ritalin-cancer.html?partner=yahootixIt's a classic growth stock that sometimes gets a little too cheap. Act quickly to accumulate this keeper.http://www.forbes.com/2009/09/16/celgene-biotechnology-thalomid-personal-finance-investing-ideas-ritalin-cancer.html?partner=yahootixCelgene CorporationWed, 16 Sep 2009 21:15:00 GMThttp://www.pharmaceutical-business-review.com/news/celgene_exercises_option_to_drug_discovery_collaboration_with_ptc_090902PTC Therapeutics (PTC) has reported that Celgene has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC's GEMST (Gene Expression Modulation by Small-molecules) technology.http://www.pharmaceutical-business-review.com/news/celgene_exercises_option_to_drug_discovery_collaboration_with_ptc_090902Celgene CorporationWed, 02 Sep 2009 11:49:26 GMThttp://www.patentbaristas.com/archives/2009/08/27/should-patients-suggestions-for-treatments-be-compensated/In 1995, Beth Jacobson’s late husband, Dr. Ira Wolmer was diagnosed with multiple myeloma; an incurable blood cancer that develops in the bone marrow. Ms. Jacobson, a lawyer, devoted her efforts to identify treatment options for her husband, which led her to request that he be treated withhttp://www.patentbaristas.com/archives/2009/08/27/should-patients-suggestions-for-treatments-be-compensated/Celgene CorporationThu, 27 Aug 2009 22:22:52 GMThttp://www.newratings.com/en/main/company_headline.m?id=1948705NEW YORK, August 6 (newratings.com) - Analysts at Cowen & Co downgrade Celgene (ticker: CELG) from "neutral" to "underperform." [more]http://www.newratings.com/en/main/company_headline.m?id=1948705Celgene CorporationThu, 06 Aug 2009 18:34:09 GMThttp://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/07-07-2009/0005055918&EDATE=This report analyzes the US market for Multiple Myeloma Therapeutics in Millions of US$. The market for multiple myeloma therapeutics is analyzed by the following Drugs: Thalomid, Revlimid, Velcade, and Others.http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/07-07-2009/0005055918&EDATE=Celgene CorporationTue, 07 Jul 2009 14:58:00 GMThttp://pubs.acs.org/cen/news/87/i21/8721news1.htmlA member supported weekly magazine of the American Chemical Society, Chemical And Engineering News covers all the news of the chemical world including science and technology, government and policy, and businesshttp://pubs.acs.org/cen/news/87/i21/8721news1.htmlCelgene CorporationMon, 18 May 2009 19:40:00 GMThttp://www.bizjournals.com/denver/stories/2009/05/11/daily85.html?ana=from_rssResearch biotech GlobeImmune Inc. has granted exclusive rights to Celgene Corp. to commercialize its cancer drug research in a deal that could mean as much as $500 million for GlobeImmune if the drugs make it to market.http://www.bizjournals.com/denver/stories/2009/05/11/daily85.html?ana=from_rssCelgene CorporationFri, 15 May 2009 20:23:02 GMThttp://www.thestreet.com/p/_yahoo/rmoney/marketcommentary/10495917.html?cm_ven=YAHOO&cm_cat=PREMIUM&cm_ite=003190Beyond the Lede: Celgene Takes Its Knocks, The company leaves its Revlimid target set too high, setting it up for disappointment.http://www.thestreet.com/p/_yahoo/rmoney/marketcommentary/10495917.html?cm_ven=YAHOO&cm_cat=PREMIUM&cm_ite=003190Celgene CorporationMon, 04 May 2009 17:31:27 GMThttp://www.canadianbusiness.com/markets/headline_news/article.jsp?content=D97TJPG00&utm_source=markets&utm_medium=rssNEW YORK (AP) - Celgene Corp. shares fell Friday as analysts voiced concern over the sales performance its key drug and its high research spending, even after the company reported first-quarter profit and revenue that narrowly beat expectations. The stock shed $2.59, or 6.1 percent, to $40.http://www.canadianbusiness.com/markets/headline_news/article.jsp?content=D97TJPG00&utm_source=markets&utm_medium=rssCelgene CorporationFri, 01 May 2009 18:17:00 GMThttp://news.yahoo.com/s/nm/20090102/bs_nm/us_citynational_probeThe Treasury Departments inspector general is examining the decision to award bailout funds to City National Corps City National Bank, the Los Angeles Times reported. News, Headlines and Latest Stories on Yahoo! Newshttp://news.yahoo.com/s/nm/20090102/bs_nm/us_citynational_probeCelgene CorporationFri, 02 Jan 2009 09:26:34 GMThttp://biz.yahoo.com/tm/081231/18661.html?.v=2TradingMarkets 7 Stocks You Need to Know for Friday. - Despite a difficult and volatile year, traders and investors managed to end the year on the positive note, with the Dow, Nasdaq and S&P 500 all closing in the green on New Year's Eve.http://biz.yahoo.com/tm/081231/18661.html?.v=2Celgene CorporationThu, 01 Jan 2009 04:45:00 GMThttp://www.istockanalyst.com/article/viewarticle+articleid_2830999.htmlAbbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8%http://www.istockanalyst.com/article/viewarticle+articleid_2830999.htmlCelgene CorporationTue, 25 Nov 2008 14:14:00 GMThttp://online.barrons.com/article/SB122704594352438727.html?mod=yahoobarrons&ru=yahooWe are upgrading Home Depot given our belief that the currently pervasive levels of fear and negativity are unsustainable. We are not calling for the turn of the housing cycle or an end to the bear market.http://online.barrons.com/article/SB122704594352438727.html?mod=yahoobarrons&ru=yahooCelgene CorporationWed, 19 Nov 2008 15:55:17 GMThttp://us.rd.yahoo.com/finance/external/tsmfe/rss/SIG=126a5snmg/*http://www.thestreet.com/_yahoo/newsanalysis/investing/10445421.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NAJonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.http://us.rd.yahoo.com/finance/external/tsmfe/rss/SIG=126a5snmg/*http://www.thestreet.com/_yahoo/newsanalysis/investing/10445421.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NACelgene CorporationMon, 03 Nov 2008 14:12:38 GMThttp://www.contractpharma.com/news/2008/10/27/methylgene_reacquires_rights_from_celgeneCelgene has terminated its licensing agreement with MethylGene for oncology histone deacetylase (HDAC) inhibitors, including MGCD0103. As a result, MethylGene will reacquire the rights to these programs.http://www.contractpharma.com/news/2008/10/27/methylgene_reacquires_rights_from_celgeneCelgene CorporationMon, 27 Oct 2008 14:22:00 GMThttp://www10.nytimes.com/2008/10/02/business/02imclone.html?_r=5&partner=rssnyt&emc=rssEli Lilly’s offering for ImClone Systems would be higher than the hostile $4.7 billion offer that Bristol-Myers Squibb has made for the shares of ImClone it does not already own.http://www10.nytimes.com/2008/10/02/business/02imclone.html?_r=5&partner=rssnyt&emc=rssCelgene CorporationThu, 02 Oct 2008 04:46:10 GMT